Genetix, a leading provider of solutions for imaging and image analysis, announces the availability of an independent, peer-reviewed publication comparing cytotoxicity testing using its CloneSelect Imager system against the conventional, widely-used, colorimetric MTT assay. The work was performed at the Leiden Institute of Chemistry, Leiden University and published in BioMed Central Biotechnology.
Entitled ‘Accurate non-invasive image-based cytotoxicity assays for cultured cells’, the paper concludes: “This new image-based technique has the potential to replace the cumbersome MTT assay when fast, unbiased and high-throughput cytotoxicity determination is required.”
Charles de Rohan, head of the Genetix Business Unit within Leica Microsystems, added, “Apart from the advantages of speed and ease of use, the label-free, non-destructive imaging technique used by the CloneSelect Imager system offers the unique possibility to directly analyze cell proliferation and cell death as a function of time, thereby revealing the effect of potential cytotoxic agents and generating a dose response curve.”
CloneSelect Imager provides a non-invasive, image-based alternative to MTT assays. As no staining is required the use of colorimetric kits is avoided, saving both time and cost. Using white light imaging and advanced image analysis, the system is used to track cell growth in each well of a microplate, accurately determining cell confluence and estimating cell number. Screening of a 96 well plate is extremely fast, with data acquisition in less than three minutes. Data can be displayed visually and exported for further analysis.
Filed Under: Drug Discovery
